243
Participants
Start Date
August 8, 2023
Primary Completion Date
October 31, 2024
Study Completion Date
October 31, 2024
Natrunix
Natrunix is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor. Natrunix blocks inflammation in a unique way-it is the only therapeutic that exclusively neutralizes interleukin-1α (IL-1α), a crucial mediator of interleukin-1 inflammation. Targeting IL-1α directly using a natural human monoclonal antibody may provide a safer and more effective means of blocking interleukin-1 in rheumatoid arthritis.
Placebo
Placebo
Altoona Center for Clinical Research, Duncansville
Reliable Clinical Research, LLC, Hialeah
Angels Clinical Research Institute, Miami
D&H National Research Centers, Miami
BioMed Research & Medical Center, LLC, Miami
DH Tamarac Research Center, Tamarac
HARAC Research Corp, Avon Park
Advanced Clinical Research of Orlando, Ocoee
Greater Chicago Specialty Physicians, LLC, Schaumburg
Greater Chicago Specialty Physicians, LLC, Orland Park
Accurate Clinical Research Inc, Lake Charles
ClinRx Research Joseph INC, Carrollton
Epic Medical Research, LLC, Red Oak
Southwest Rheumatology Research, LLC, Mesquite
Accurate Clinical Management LLC, Houston
Accurate Clinical Research Inc, Houston
Pioneer Research Solutions, INC, Houston
DM Clinical Research, Tomball
Accurate Clinical Management, LLC, Richmond
Medvin Clinical Research, Tujunga
T. Joseph Raoof MD, INC, Encino
Medvin Clinical Research, Covina
Inland Rheumatology Clinical Trials, Inc., Upland
Desert Medical Advances, Rancho Mirage
Medvin Clinical Research, Riverside
Overlake Arthritis and Osteoporosis Center, Bellevue
XBiotech, Inc.
INDUSTRY